Key strategies for a successful European drug launch
We recently hosted a webinar focused on essential strategies for launching orphan drugs successfully in the European market. Our latest whitepaper brings you the key takeaways.
Our expert panel included, Raymond A. Huml, Vice President of Rare Strategy at Sciensus, and Andrew Cummins, Vice President of Business Development at Sciensus, along with Kirsty Hoyle, CEO of Metabolic Support UK.
The session examined the complexities involved in bringing a new product to market in Europe and highlighted how pharma and biotech companies can navigate these challenges to achieve success. Expert panellists discussed various partnership models aligned with different organisational objectives, and the growing impact of digital technologies in enhancing patient access and adherence.
The conversation also underscored the critical contribution of patient advocacy groups, the importance of early stakeholder engagement, and the need to prioritise equity, diversity, and inclusion throughout the launch process.
Webinar insights: strategic planning for drug launches in Europe
In this paper we cover how to:
- Navigate European regulatory hurdles effectively
- Choose the right partnership for your organisation
- Engage early with patient advocacy groups to drive success
- Leverage digital innovation to improve patient access and treatment adherence for orphan drugs
- Prioritise equity, diversity, and inclusion when launching a new orphan drug in Europe
Download this free paper for strategic insights on launching orphan drugs in Europe.
Our Sciensus expert speakers
About Sciensus
Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.
Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.